10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2022 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 22, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Operating Activities: | |||
| Net income | $ 4,566 | 6,201 | 89 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 323 | 329 | 288 |
| Amortization expense | 1,780 | 1,721 | 1,192 |
| Stock-based compensation expense | 637 | 635 | 643 |
| Deferred income taxes | (1,552) | (116) | (214) |
| Net loss from equity securities | 657 | 610 | 1,662 |
| Acquired in-process research and development expenses | 944 | 939 | 5,968 |
| In-process research and development impairment | 2,700 | 0 | 0 |
| Other | 780 | 576 | 178 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (406) | 313 | (1,171) |
| Inventories | (310) | 11 | (195) |
| Prepaid expenses and other | 70 | (42) | (214) |
| Accounts payable | 226 | (118) | 80 |
| Income taxes payable | (568) | (364) | (778) |
| Accrued liabilities | (775) | 689 | 640 |
| Net cash provided by operating activities | 9,072 | 11,384 | 8,168 |
| Investing Activities: | |||
| Purchases of marketable debt securities | (1,770) | (3,517) | (20,315) |
| Proceeds from sales of marketable debt securities | 412 | 730 | 23,239 |
| Proceeds from maturities of marketable debt securities | 1,590 | 2,180 | 9,479 |
| Acquisitions, including in-process research and development, net of cash acquired | (1,797) | (1,584) | (25,920) |
| Purchases of equity securities | (172) | (380) | (455) |
| Capital expenditures | (728) | (579) | (650) |
| Other | (1) | 19 | 7 |
| Net cash used in investing activities | (2,466) | (3,131) | (14,615) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 0 | 0 | 8,184 |
| Proceeds from issuances of common stock | 309 | 169 | 256 |
| Repurchases of common stock | (1,396) | (546) | (1,583) |
| Repayments of debt and other obligations | (1,500) | (4,750) | (2,500) |
| Payment of dividends | (3,709) | (3,605) | (3,449) |
| Other | (173) | (145) | (138) |
| Net cash provided by (used in) financing activities | (6,469) | (8,877) | 770 |
| Effect of exchange rate changes on cash and cash equivalents | (63) | (35) | 43 |
| Net change in cash and cash equivalents | 74 | (659) | (5,634) |
| Cash and cash equivalents at beginning of period | 5,338 | 5,997 | |
| Cash and cash equivalents at end of period | 5,412 | 5,338 | 5,997 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 907 | 979 | 951 |
| Income taxes paid | 3,136 | 2,509 | 2,639 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |